Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib and Ritlecitinib in Newly Diagnosed Type 1 Diabetes
NCT05743244Phase 2Active, not recruiting
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of abrocitinib, ritlecitinib tosilate in type 1 diabetes mellitus (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Oct 2023; status: active, not recruiting.
02
Drugs
abrocitinibritlecitinib tosilate
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05743244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743244.